What it is
Bronchogen is a peptide bioregulator. Both halves of that name matter.
A peptide is a chain of amino acids. Bioregulators are the short ones — shorter than the peptides on most of this site. Being small has a practical consequence: there is less for the immune system to object to, so the risk of an unwanted immune reaction is lower.
The "bioregulator" part describes how they work. Most peptides send signals to cells from the outside, and the effect lasts only while the peptide is there. Bioregulators go further in: each one is matched to a particular tissue, and inside that tissue it binds to DNA and changes which genes are switched on or off. Because the genes involved govern repair, regeneration, and ageing, their effects are described as more foundational and longer-lasting than ordinary peptides, which stop working once dosing stops.
Bronchogen's tissue is the bronchopulmonary system — the lungs and the bronchi, the airways branching from the windpipe into each lung. Its stated purpose is to restore balance in lung tissue, in the bronchi, and in breathing function overall.
It comes as a dry powder, mixed with bacteriostatic water — sterile water with a preservative so the mixed liquid keeps — and drawn up in an insulin syringe.
Bronchogen is a short peptide bioregulator with tropism for the bronchopulmonary system, described as restoring homeostatic balance in pulmonary tissue, the bronchial tree, and respiratory function.
The class distinction: bioregulators are shorter-chain than conventional therapeutic peptides, and their reduced size lowers immunogenic potential. Mechanistically they are described as tissue-specific DNA-binding agents that regulate gene expression within their target tissue, rather than as extracellular signalling ligands. The claimed consequence is durability — activation or suppression of genes governing repair, regeneration, and longevity is framed as producing effects that persist beyond the dosing window, in contrast to signalling peptides whose action is confined to the period of exposure.
No gene targets, binding sites, or supporting data have been identified for this mechanistic account.
Presentation is a lyophilised powder reconstituted with bacteriostatic water and dosed in insulin units. Note that the route of administration has not been specified — every other bioregulator on this site is given subcutaneously, while for Bronchogen only reconstitution and unit doses are defined. The injectable classification here follows from the reconstitution and unit dosing rather than from an explicitly stated route.
Vial mass is likewise unspecified and has been derived from the unit-to-microgram conversions in the dosing chart; see the dosing notes.
What it does
The central claim is repair of the cells lining the lungs and the bronchi, making that tissue more resilient. From there the effects follow the same tissue: it supports normal working of lung tissue and airways by influencing how those cells repair and regenerate themselves.
Several of the applications are about recovery. It is used in rehabilitation after respiratory infections, after exposure to toxic substances, and after a period on a ventilator. It supports the return of bronchial tissue to normal after a viral or bacterial chest illness.
Several are about long-running conditions. It may help in managing chronic bronchitis, asthma, and repeated bouts of inflammation in the airways, and it reduces the impact of allergic and inflammatory responses in the bronchial system.
It balances inflammatory signalling, which may reduce irritation and twitchiness in the airways, and it strengthens the local immune defences of the respiratory tract against environmental stresses.
By keeping the structure of the airways intact, it may indirectly support better oxygen intake. And it is being investigated for keeping the structure and function of respiratory tissue in older people, where that tissue naturally declines.
Cellular regeneration of bronchial and pulmonary epithelium, with the stated aim of tissue resilience, is the primary described action. Regulation of the respiratory system follows from it: support of normal lung and bronchial function through modulation of cellular repair and regeneration.
Inflammatory and immune: balancing of inflammatory signalling with possible reduction in airway irritation and hyperreactivity; reduced impact of inflammatory responses in allergic and inflammatory bronchial disorders; strengthened local respiratory tract immune defence and resilience to environmental stressors.
Clinical applications named: management adjunct in chronic bronchitis, asthma, and recurrent bronchial inflammatory processes; pulmonary rehabilitation following respiratory infection, toxic exposure, or mechanical ventilation; normalisation of bronchial tissue after viral or bacterial respiratory illness; investigation in age-related respiratory decline for maintenance of tissue structure and function.
Gas exchange: improved oxygen intake is described as an indirect consequence of maintained structural integrity of the bronchial pathways rather than a direct effect.
Gene expression: influence on epigenetic regulation of proteins associated with pulmonary tissue health, repair, and immune defence — consistent with the class mechanism above, though again without named targets.
Positioning: described as a therapeutic adjunct capable of complementing conventional respiratory treatment by enhancing natural tissue recovery and lowering relapse risk, rather than as a replacement for it.
Benefits
Evidence grades: what the labels mean
- Human trials Supported by randomised or placebo-controlled human trials.
- Limited human data Some human evidence, such as pilot studies, case reports or observational data, but no controlled trials.
- Animal or lab only Shown in animal or cell studies only; not yet tested in people.
- Anecdotal No published studies; based on user reports or theory.
Each grade reflects the strongest published support for that specific claim, not for the compound as a whole.
- Improves repair of the cells lining the bronchi and lungs, making that tissue more resilient.Animal or lab only
- Supports the normal working of lung tissue and the airways by influencing how those cells repair and regenerate.Animal or lab only
- May help in managing chronic bronchitis, asthma, and repeated bouts of airway inflammation.Anecdotal
- Used in recovery support after respiratory infections, after exposure to toxic substances, or after time on a ventilator.Anecdotal
- Reduces the impact of inflammatory responses in the bronchial system, relevant to allergic and inflammatory disorders.Animal or lab only
- Being investigated for keeping the structure and function of respiratory tissue intact in older people.Anecdotal
- Supports the return of bronchial tissue to normal after a viral or bacterial chest illness.Anecdotal
- Balances inflammatory signalling, which may reduce airway irritation and twitchiness.Animal or lab only
- By keeping the airways structurally sound, may indirectly support better oxygen intake.Anecdotal
- Influences the regulation of proteins associated with tissue health, repair, and immune defence in the lungs.Animal or lab only
- Strengthens the local immune defences of the respiratory tract, improving resilience to environmental stresses.Animal or lab only
- Can complement conventional treatments for respiratory illness by supporting natural tissue recovery and lowering the risk of relapse.Anecdotal
- Cellular regeneration: enhanced repair of bronchial and pulmonary epithelial cells, promoting tissue resilience.Animal or lab only
- Respiratory system regulation: supports normal lung and bronchial function by modulating cellular repair and regeneration.Animal or lab only
- Chronic bronchial conditions: possible management adjunct in chronic bronchitis, asthma, and recurrent bronchial inflammatory processes.Anecdotal
- Pulmonary rehabilitation: recovery support following respiratory infection, toxic exposure, or mechanical ventilation.Anecdotal
- Allergic and inflammatory disorders: reduces the impact of inflammatory responses in the bronchial system.Animal or lab only
- Age-related respiratory decline: investigated for maintenance of respiratory tissue structure and function in older populations.Anecdotal
- Post-infection recovery: supports normalisation of bronchial tissue after viral or bacterial respiratory illness.Anecdotal
- Anti-inflammatory: balances inflammatory signalling, potentially reducing airway irritation and hyperreactivity.Animal or lab only
- Improved oxygen exchange, described as indirect — a consequence of maintained bronchial structural integrity.Anecdotal
- Gene expression modulation: influences epigenetic regulation of proteins associated with pulmonary tissue health, repair, and immune defence.Animal or lab only
- Immune support: strengthens local respiratory tract immune defence and resilience to environmental stressors.Animal or lab only
- Therapeutic adjunct: complements conventional respiratory treatment by enhancing natural tissue recovery and lowering relapse risk.Anecdotal
Reconstitution and dosing
Mix the vial with 3 millilitres (mL) of bacteriostatic water. On an insulin syringe that is the 300 mark, because 100 units is 1 mL. Add the water slowly down the inside wall of the vial rather than onto the powder, then swirl gently. Do not shake.
About the vial size. The amount of peptide in the vial is not specified. It can be worked out from the dosing numbers. 30 units is 2 milligrams, and one unit is one hundredth of a millilitre, so that is about 67 micrograms in every unit — which over 3 mL comes to 20 milligrams in the vial. Every other bioregulator on this site comes in a 20 mg vial, which fits. That is the figure the table below uses, and it is derived rather than confirmed. If your vial is a different size, the draws will be wrong.
With 20 mg in 3 mL, the draws come out at 7.5 units for 500 micrograms and 30 units for 2 milligrams. The dosing chart rounds the first of those to 8 units rather than 7.5 — a difference of about 7%, which is rounding up to a mark you can see on the syringe. The second matches exactly.
How to administer it has not been specified. Every other bioregulator on this site is injected under the skin, and the reconstitution and unit dosing here only make sense for an injection, but the route has not been confirmed.
Dose at bedtime, two hours after your last meal. Take it six days a week, with one day off, for the whole 40 days.
A cycle runs 40 days, and can be repeated after three to six months.
The dose steps up sharply. The first seven days are 500 micrograms. From day 8 to day 40 it is 2 milligrams — four times as much — and holds there for the remaining five weeks.
Reconstitution: 3 mL (300 units) of bacteriostatic water. Add down the vial wall and swirl; do not shake.
Derived vial mass. No vial size is specified. The unit-to-microgram pairs are 8 units = 500 mcg and 30 units = 2 mg, implying 62.5 and 66.7 mcg per unit respectively. 20 mg in 3 mL — 6.67 mg/mL, 66.7 mcg per unit — reproduces the second exactly and the first within rounding, and matches the 20 mg presentation used by every other bioregulator on this site. The protocol below uses vialMg = 20, waterMl = 3 on that basis; the figure is derived from the unit-to-microgram arithmetic rather than specified. Verify against the actual vial.
Recomputed draws at 20 mg / 3 mL (66.67 mcg per unit): 500 mcg = 7.5 units (rounded to 8); 2,000 mcg = 30 units (exact). Divergence of 6.7% at the first step and exact agreement at the second — syringe-mark rounding, nothing above 10%.
Route is not specified. Every other bioregulator on this site is administered subcutaneously; for Bronchogen only reconstitution volume and unit doses are defined. The injectable classification follows from that rather than from an explicit statement, and no route preference — subcutaneous against intramuscular — has been established.
Administration: bedtime, two hours after the last meal, six consecutive days per week with one day off, throughout the 40-day course. No rationale is given for the timing, the postprandial interval, or the weekly day off.
Cycle: 40 days, repeatable after 3–6 months.
Titration: 500 mcg daily for days 1–7, then 2 mg daily for days 8–40 — a fourfold step at day 8 with no intermediate stage, unusually abrupt against the graded escalations elsewhere on this site. Total exposure across a cycle is 3 mg across the loading week (6 dosing days × 500 mcg) plus about 57 mg thereafter, i.e. three 20 mg vials per cycle at the derived vial mass.
20 mg vial (vial size derived — see dosing notes)
Mix with 3 mL (300 units) of BAC water. The vial mass is not specified; 20 mg is derived from the dosing figures (30 units = 2 mg implies 66.7 mcg per unit, i.e. 6.67 mg/mL over 3 mL), and matches the 20 mg presentation of the other bioregulators on this site. The route of administration is also not specified. Check the vial you actually have before dosing.
6.67 mg/mL · 66.67 mcg per unit
Cycle: 40-day cycle; may be repeated after 3–6 months · Frequency: 1×/day at bedtime, 2 hours after the last meal; 6 days on, 1 day off each week
| When | Dose | Draw | How often |
|---|---|---|---|
| Days 1–7 (500 mcg — 8 units on the syringe, computed 7.5) | 500 mcg | 7.5 units | 1×/day, 6 consecutive days per week |
| Days 8–40 (2 mg) | 2 mg | 30 units | 1×/day, 6 consecutive days per week |
20 mg in 3 mL is 6.67 mg/mL, or 66.67 mcg per unit. Draw 7.5 units (0.075 mL) for 500 mcg.
Who should avoid it
- No contraindications have been documented for Bronchogen, which sets it apart from most of the other bioregulators on this site. Treat that as missing information, not as clearance for everyone.
- No medicine interactions have been documented, so none have been ruled out. This matters here more than usual, because the compound is aimed at conditions — asthma, chronic bronchitis — that are normally already being treated with inhalers, steroids, or other prescriptions. Go through your full medication list with a doctor before starting.
- There is no information on pregnancy, breastfeeding, or use in anyone under 18 either way. The other bioregulators on this site exclude all three, and the lack of information here is a gap in the data rather than a difference in the compound.
- The other bioregulator pages on this site all exclude anyone who has reacted badly to a peptide product before. The same caution reasonably applies to this one.
- Bronchogen is described as something that complements conventional treatment, not something that replaces it. Do not stop a prescribed respiratory medicine to make room for it.
- Talk to a doctor before starting.
- No contraindication list has been established — an omission relative to the other bioregulators on this site, not a distinguishing property of the compound. Read it as absent documentation.
- No drug interactions are documented. The gap is material given that the named indications — asthma, chronic bronchitis, post-ventilation rehabilitation — describe populations on established respiratory pharmacotherapy, frequently including inhaled or systemic corticosteroids.
- Pregnancy, lactation, and paediatric use are unaddressed. Every other bioregulator page on this site excludes them.
- Peptide hypersensitivity is the standard exclusion across this class on the other pages here and reasonably applies.
- Worth reading as a limit: the compound is positioned as a therapeutic adjunct complementing conventional treatment, not as a substitute for it.
Side effects
- No side effects have been documented, which again sets it apart from most of the other bioregulators on this site. That is an absence of information, not a claim that there are none.
- Any injection can leave redness, swelling, or itching at the spot. Every other bioregulator page on this site lists that.
- Those pages also list rare allergic reactions in people who turn out to be sensitive to peptide products. The same possibility applies here.
- One thing the dosing instructions hint at: this is taken at bedtime, two hours after eating. No reason has been given, and no side effect is named to explain it.
- No adverse effect list has been documented — an omission relative to the other bioregulators here rather than a claim of none.
- Injection site reactions — erythema, swelling, pruritus — are listed on every other bioregulator page on this site and are generic to the route.
- Rare hypersensitivity reactions in peptide-sensitive individuals are likewise listed across the class here.
- Unexplained administration constraint: bedtime dosing two hours postprandially, with no rationale given and no adverse effect named that would account for either the timing or the fasting interval.
User reports
User reports are individual experiences submitted by site visitors. They are not medical advice, are not verified for accuracy, and do not reflect Amino Reference's views. Read the evidence section above and talk to a clinician. Full disclaimer.
Stacking
Not an established pairing — no stacks have been defined for Bronchogen. Listed because it is the immune bioregulator on this site, and several of Bronchogen's stated uses — recovery after a chest infection, resilience against environmental stress — sit on the same ground. Read Crystagen's own page first: unlike this one, it has a real list of people who should not use it.
Not an established pairing; listed on overlapping ground. Bronchogen's stated local respiratory immune defence and post-infective normalisation share territory with Crystagen's systemic immune normalisation. Crystagen's entry carries substantive contraindications — autoimmune disease, immunosuppression, active malignancy — that are absent for Bronchogen and that would govern the combination.
- No established stacks
No compound has been established as a pairing for Bronchogen. The entry above is a cross-reference to a related page on this site, not an established recommendation.
No stacking data exists for Bronchogen, and unlike several sibling bioregulators no interaction data is documented either. The cross-reference above is editorial.
Dosing figures have been reviewed and units are recomputed from the stated protocol.